These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33934008)

  • 1. Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.
    Liu YM; Tu HJ; Wu CH; Lai MJ; Yu SC; Chao MW; Wu YW; Teng CM; Pan SL; Liou JP
    Eur J Med Chem; 2021 Jul; 219():113428. PubMed ID: 33934008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
    Wu WC; Liu YM; Liao YH; Hsu KC; Lien ST; Chen IC; Lai MJ; Li YH; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Oct; 203():112540. PubMed ID: 32683166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
    Jeong JH; Oh YJ; Lho Y; Park SY; Liu KH; Ha E; Seo YH
    Eur J Med Chem; 2016 Nov; 124():1069-1080. PubMed ID: 27783977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1 H-pyrazol-4-yl)-1 H-imidazol-1-yl)-1 H-pyrazolo[3,4- b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor.
    Uno T; Kawai Y; Yamashita S; Oshiumi H; Yoshimura C; Mizutani T; Suzuki T; Chong KT; Shigeno K; Ohkubo M; Kodama Y; Muraoka H; Funabashi K; Takahashi K; Ohkubo S; Kitade M
    J Med Chem; 2019 Jan; 62(2):531-551. PubMed ID: 30525599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
    Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
    Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
    Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-NSCLC activity in vitro of Hsp90
    Li HJ; Wang QS; Han W; Zhou H; Li P; Zhou F; Qin W; Zhao D; Zhou X; He CX; Xing L; Li PQ; Jin X; Yu F; He JH; Cao HL
    J Struct Biol; 2021 Jun; 213(2):107710. PubMed ID: 33610655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
    Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
    Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
    Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
    Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
    Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR
    Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.
    Zhang Y; Zhang TJ; Li XY; Liang JW; Tu S; Xu HL; Xue WH; Qian XH; Zhang ZH; Zhang X; Meng FH
    Eur J Med Chem; 2021 Jan; 210():112988. PubMed ID: 33189438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R; Huang HL; HuangFu WC; Wu YW; Nepali K; Lai MJ; Su CJ; Sung TY; Chen YL; Pan SL; Liou JP
    Eur J Med Chem; 2018 Apr; 150():667-677. PubMed ID: 29567459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
    Zhao H; Anyika M; Girgis A; Blagg BS
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3633-7. PubMed ID: 24953820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer.
    Graham B; Curry J; Smyth T; Fazal L; Feltell R; Harada I; Coyle J; Williams B; Reule M; Angove H; Cross DM; Lyons J; Wallis NG; Thompson NT
    Cancer Sci; 2012 Mar; 103(3):522-7. PubMed ID: 22181674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
    Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
    Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.